Raymond James analyst Danielle Brill reiterated a Market Perform rating on Global Blood Therapeutics (NASDAQ: GBT) after hosting a sickle ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE